Résultats de la recherche - O’Brien, Eric
- Résultat(s) 1 - 9 résultats de 9
-
1
-
2
81030 Utilizing a synergistic drug combination to target relapsed/refractory FLT3 mutant AML par Jones, LaQuita, Melgar, Katelyn, Hoyt, Scott, Wunderlich, Mark, O’Brien, Eric, Perentesis, John, Thomas, Craig, Starczynowski, Daniel
Publié 2021Texte -
3
Improved chemotherapy modeling with RAG-based immune deficient mice par Wunderlich, Mark, Manning, Nicole, Sexton, Christina, Sabulski, Anthony, Byerly, Luke, O’Brien, Eric, Perentesis, John P., Mizukawa, Benjamin, Mulloy, James C.
Publié 2019Texte -
4
PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia par Wunderlich, Mark, Manning, Nicole, Sexton, Christina, O’Brien, Eric, Byerly, Luke, Stillwell, Cody, Perentesis, John P., Mulloy, James C., Mizukawa, Benjamin
Publié 2021Texte -
5
The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation par Mizukawa, Benjamin, O’Brien, Eric, Moreira, Daniel C., Wunderlich, Mark, Hochstetler, Cindy L., Duan, Xin, Liu, Wei, Orr, Emily, Grimes, H. Leighton, Mulloy, James C., Zheng, Yi
Publié 2017Texte -
6
Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia par Hayashi, Yasutaka, Goyama, Susumu, Liu, XiaoXiao, Tamura, Moe, Asada, Shuhei, Tanaka, Yosuke, Fukuyama, Tomofusa, Wunderlich, Mark, O’Brien, Eric, Mizukawa, Benjamin, Yamazaki, Satoshi, Matsumoto, Akiko, Yamasaki, Satoshi, Shibata, Tatsuhiro, Matsuda, Koichi, Sashida, Goro, Takizawa, Hitoshi, Kitamura, Toshio
Publié 2019Texte -
7
miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential par Meyer, Sara E., Muench, David E., Rogers, Andrew M., Newkold, Tess J., Orr, Emily, O’Brien, Eric, Perentesis, John P., Doench, John G., Lal, Ashish, Morris, Patrick J., Thomas, Craig J., Lieberman, Judy, McGlinn, Edwina, Aronow, Bruce J., Salomonis, Nathan, Grimes, H. Leighton
Publié 2018Texte -
8
Targeting AML-associated FLT3 mutations with a type I kinase inhibitor par Jones, LaQuita M., Melgar, Katelyn, Bolanos, Lyndsey, Hueneman, Kathleen, Walker, Morgan M., Jiang, Jian-Kang, Wilson, Kelli M., Zhang, Xiaohu, Shen, Jian, Jiang, Fan, Sutter, Patrick, Wang, Amy, Xu, Xin, Tawa, Gregory J., Hoyt, Scott B., Wunderlich, Mark, O’Brien, Eric, Perentesis, John P., Starczynowski, Daniel T., Thomas, Craig J.
Publié 2020Texte -
9
Overcoming adaptive therapy resistance in AML by targeting immune response pathways par Melgar, Katelyn, Walker, Morgan M., Jones, LaQuita M., Bolanos, Lyndsey C., Hueneman, Kathleen, Wunderlich, Mark, Jiang, Jiang-Kang, Wilson, Kelli M., Zhang, Xiaohu, Sutter, Patrick, Wang, Amy, Xu, Xin, Choi, Kwangmin, Tawa, Gregory, Lorimer, Donald, Abendroth, Jan, O’Brien, Eric, Hoyt, Scott B., Berman, Ellin, Famulare, Christopher A., Mulloy, James C., Levine, Ross L., Perentesis, John P., Thomas, Craig J., Starczynowski, Daniel T.
Publié 2019Texte